Pembrolizumab plus chemotherapy in squamous non–small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study

S Novello, DM Kowalski, A Luft, M Gümüş… - Journal of Clinical …, 2023 - ascopubs.org
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …
被引用次数：212 相关文章

Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

S Novello, DM Kowalski, A Luft, M Gümüş, D Vicente… - 2023 - pubmed.ncbi.nlm.nih.gov
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.

S Novello, DM Kowalski, A Luft, M Gümüş… - Journal of Clinical …, 2023 - europepmc.org
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

[引用][C] Pembrolizumab Plus Chemotherapy in Squamous Non Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

S Novello, DM Kowalski, A Luft… - Journal of Clinical …, 2023 - ub01.uni-tuebingen.de
Pembrolizumab Plus Chemotherapy in Squamous Non Small-Cell Lung Cancer: 5-Year
Update of the Phase III KEYNOTE-407 Study Pembrolizumab Plus Chemotherapy in Squamous …

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

S Novello, DM Kowalski, A Luft… - Journal of Clinical …, 2023 - ingentaconnect.com
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

S Novello, DM Kowalski, A Luft… - Journal of Clinical …, 2023 - einstein.elsevierpure.com
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

[引用][C] Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

S Novello, DM Kowalski, A Luft… - Journal of Clinical …, 2023 - produccioncientifica.ucm.es
[HTML] nih.gov

[HTML][HTML] Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

S Novello, DM Kowalski, A Luft, M Gümüş… - Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

[引用][C] Pembrolizumab Plus Chemotherapy in Squamous Non Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

S Novello, DM Kowalski, A Luft… - Journal of …, 2023 - tobias-lib.ub.uni-tuebingen.de
Pembrolizumab Plus Chemotherapy in Squamous Non Small-Cell Lung Cancer: 5-Year
Update of the Phase III KEYNOTE-407 Study Pembrolizumab Plus Chemotherapy in Squamous …

Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

S Novello, DM Kowalski, A Luft, M Gümüş… - JOURNAL OF …, 2023 - iris.unito.it
: Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …